TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02832791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QUADRICEPS TENDON
Description: Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAMSTRING TENDON
Description: Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper
Study: NCT02220140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Resilience Program
Description: See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
Study: NCT03221439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Motor Control Exercise
Description: According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
Study: NCT00634283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: venlafaxine IR 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine IR 150mg
Study: NCT01565382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
Study: NCT02921347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: switching between invasive and noninvasive ventilation
Description: As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
Study: NCT03596918

Intervention type: BIOLOGICAL
Intervention: Bleomycin Sulfate
Description: Given IV

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03083132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: modafinil 50mg
Description: 1 capsule oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modafinil 50mg
Description: 1 capsule oral daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule oral daily
Study: NCT03503708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livitol-70
Description: Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
Study: NCT01050166

Intervention type: OTHER
Intervention: Transplantation of labeled islets
Study: NCT01538706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based home care
Description: Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
Study: NCT03395574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: drug will be given after 30 minutes of induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: drug will be given after 30 minutes as placebo in control group
Study: NCT00737321

Intervention type: PROCEDURE
Intervention: Samples will be collected
Description: wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
Study: NCT03999281

Intervention type: OTHER
Intervention: Human Allograft (Theraskin)
Description: Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.

Intervention type: OTHER
Intervention: Human Allograft (Theraskin)
Description: Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
Study: NCT00878449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide/cisplatin
Description: etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
Study: NCT02880215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Behavioral intervention designed to decrease negative attention bias.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Behavioral intervention designed to improve sustained attention.
Study: NCT01452113

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin
Description: one 50 mg tablet per os

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin
Description: one 50 mg tablet per os
Study: NCT02555618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-850
Description: TAK-850 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza HA vaccine
Description: Influenza HA vaccine subcutaneous injection
Study: NCT03676959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 5mg/kg
Description: 5mg/kg/times bi-week IV administration of ZKAB001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 10mg/kg
Description: 10mg/kg/times bi-week IV administration of ZKAB001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 15mg/kg
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Study: NCT01528566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
Study: NCT01497574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
Study: NCT04310748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Intravenous Anesthesia(TIVA)
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Anesthesia
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded.
Study: NCT03941223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECSII and paravertebral blocks
Description: Regional anesthesia for mastectomy outcomes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECSII and paravertebral blocks
Description: Regional anesthesia for mastectomy outcomes
Study: NCT03335709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADL intervention
Description: Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
Study: NCT03957278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe System
Description: The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
Study: NCT01824459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1：40\~60mg bid，d1\~14 q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1：40\~60mg bid，d1\~14 q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin：60mg/m2，iv drip ，d1,q3W
Study: NCT00838500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate spa treatment
Description: 1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Late spa treatment
Description: 2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
Study: NCT03425149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline (PBS)
Study: NCT00746837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 50 mg od, 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 150mg od, 12 days
Study: NCT00538187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV
Study: NCT03116919

Intervention type: OTHER
Group type: OTHER
Intervention: Potato
Description: Participants will be given an extra serving of potato a day

Intervention type: OTHER
Group type: OTHER
Intervention: Non-starchy vegetable
Description: Participants will be given an extra serving of a non-starchy vegetable
Study: NCT01895387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention-whole grains and legumes
Description: Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention-Refined rice
Description: Subjects in the control group maintained their usual diet of refined rice
Study: NCT03727750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
Study: NCT00538187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative study
Study: NCT04180254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effect of several processing on the auditory distance perception
Description: The focus is a comparison of hearing instrument algorithms on the auditory distance perception
Study: NCT03876288

Intervention type: DEVICE
Intervention: GI Neuromodulation
Description: The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
Study: NCT02138591

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw pre-operatively
Description: Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw pre-operatively
Description: Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
Study: NCT03876288

Intervention type: DRUG
Intervention: Immunotherapy
Description: The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.

Intervention type: PROCEDURE
Intervention: Pyloric Therapies
Description: The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
Study: NCT03836274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES MONACO
Description: AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study: NCT02138591

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw post-operative Day 1
Description: Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw post-operative Day 1
Description: Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw post-operative Day 2
Description: Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw post-operative Day 2
Description: Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
Study: NCT04636398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESSAGE - mHealth intervention
Description: A group-based moderated six-week intervention with didactic, discussion, and text communication components.
Study: NCT04821882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: 10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
Study: NCT01461343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT imaging, functional PET imaging
Description: Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
Study: NCT06496113

Intervention type: PROCEDURE
Intervention: Minimally invasive liver resection
Description: Patients underwent liver resection either by robotic or laparoscopic approach

Intervention type: PROCEDURE
Intervention: Minimally invasive liver resection
Description: Patients underwent liver resection either by robotic or laparoscopic approach
Study: NCT00984906

Intervention type: OTHER
Group type: OTHER
Intervention: Empty inhalers
Description: Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler

Intervention type: OTHER
Group type: OTHER
Intervention: Empty inhalers
Description: Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler

Intervention type: OTHER
Group type: OTHER
Intervention: Empty inhalers
Description: Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler